Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

Benzinga Newsdesk www.benzinga.com Positive 90.3%

Neg 0% Neu 0% Pos 90.3%

Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.